statementSaid on 2026-11-11
The self-developed SHR-3201 injection has been approved by the National Medical Products Administration to conduct clinical trials, and it is intended for Alzheimer's disease.
A statement by post author, said on 2026-11-11. Statements are as reported by the cited publishers — not verified by DecisionGateway.
自主研發的SHR-3201注射液已獲國家藥監局批准開展臨床試驗,擬用於阿爾茨海默病
Discussion
Related claims
LY03017 for psychotic disorders associated with Alzheimer's disease has entered Phase II clinical trials in China and completed first dosing; LY03020, as the world's first TAAR1/5-HT2CR dual-target agonist, also lists psychotic disorders associated with Alzheimer's disease as a target indication.post author · statementCM383 has started Phase Ib clinical trials for mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease, and some brokerages regard it as a potential leading Aβ antibody in China; CM559 has also advanced to Phase I clinical trials.post author · statementSIM0725 has been approved by the National Medical Products Administration to conduct clinical trials in China.先聲藥業集團 · investigationSIM0725 is intended for the treatment of autoimmune diseases.先聲藥業集團 · statementAfter acquiring a controlling stake in Green Valley Pharmaceutical, Fosun incorporated sodium oligomannate capsules, used for mild to moderate Alzheimer's disease, into its innovative drug pipeline and took over its post-marketing confirmatory clinical study.post author · statementThe announcement explicitly states that no similar drug has been approved for marketing domestically or abroad.公告 · statement